Emerging Trends in Neuromodulation for Treatment of Drug-Resistant Epilepsy

Epilepsy is a neurological disorder that affects more than 70 million people globally. A considerable proportion of epilepsy is resistant to anti-epileptic drugs (AED). For patients with drug-resistant epilepsy (DRE), who are not eligible for resective or ablative surgery, neuromodulation has been a...

Descripción completa

Detalles Bibliográficos
Autores principales: Abouelleil, Mohamed, Deshpande, Nachiket, Ali, Rushna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pain Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8977768/
https://www.ncbi.nlm.nih.gov/pubmed/35386582
http://dx.doi.org/10.3389/fpain.2022.839463
_version_ 1784680834926641152
author Abouelleil, Mohamed
Deshpande, Nachiket
Ali, Rushna
author_facet Abouelleil, Mohamed
Deshpande, Nachiket
Ali, Rushna
author_sort Abouelleil, Mohamed
collection PubMed
description Epilepsy is a neurological disorder that affects more than 70 million people globally. A considerable proportion of epilepsy is resistant to anti-epileptic drugs (AED). For patients with drug-resistant epilepsy (DRE), who are not eligible for resective or ablative surgery, neuromodulation has been a palliative option. Since the approval of vagus nerve stimulation (VNS) in 1997, expansion to include other modalities, such as deep brain stimulation (DBS) and responsive neurostimulation (RNS), has led to improved seizure control in this population. In this article, we discuss the current updates and emerging trends on neuromodulation for epilepsy.
format Online
Article
Text
id pubmed-8977768
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-89777682022-04-05 Emerging Trends in Neuromodulation for Treatment of Drug-Resistant Epilepsy Abouelleil, Mohamed Deshpande, Nachiket Ali, Rushna Front Pain Res (Lausanne) Pain Research Epilepsy is a neurological disorder that affects more than 70 million people globally. A considerable proportion of epilepsy is resistant to anti-epileptic drugs (AED). For patients with drug-resistant epilepsy (DRE), who are not eligible for resective or ablative surgery, neuromodulation has been a palliative option. Since the approval of vagus nerve stimulation (VNS) in 1997, expansion to include other modalities, such as deep brain stimulation (DBS) and responsive neurostimulation (RNS), has led to improved seizure control in this population. In this article, we discuss the current updates and emerging trends on neuromodulation for epilepsy. Frontiers Media S.A. 2022-03-21 /pmc/articles/PMC8977768/ /pubmed/35386582 http://dx.doi.org/10.3389/fpain.2022.839463 Text en Copyright © 2022 Abouelleil, Deshpande and Ali. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pain Research
Abouelleil, Mohamed
Deshpande, Nachiket
Ali, Rushna
Emerging Trends in Neuromodulation for Treatment of Drug-Resistant Epilepsy
title Emerging Trends in Neuromodulation for Treatment of Drug-Resistant Epilepsy
title_full Emerging Trends in Neuromodulation for Treatment of Drug-Resistant Epilepsy
title_fullStr Emerging Trends in Neuromodulation for Treatment of Drug-Resistant Epilepsy
title_full_unstemmed Emerging Trends in Neuromodulation for Treatment of Drug-Resistant Epilepsy
title_short Emerging Trends in Neuromodulation for Treatment of Drug-Resistant Epilepsy
title_sort emerging trends in neuromodulation for treatment of drug-resistant epilepsy
topic Pain Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8977768/
https://www.ncbi.nlm.nih.gov/pubmed/35386582
http://dx.doi.org/10.3389/fpain.2022.839463
work_keys_str_mv AT abouelleilmohamed emergingtrendsinneuromodulationfortreatmentofdrugresistantepilepsy
AT deshpandenachiket emergingtrendsinneuromodulationfortreatmentofdrugresistantepilepsy
AT alirushna emergingtrendsinneuromodulationfortreatmentofdrugresistantepilepsy

Ejemplares similares